Sildenafil
Brand names: Viagra · Active ingredient: Sildenafil Citrate
In short: Sildenafil tablets are indicated for the treatment of erectile dysfunction.
What is Sildenafil used for?
Sildenafil tablets are indicated for the treatment of erectile dysfunction.
Sildenafil dosage
For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, Sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity. The maximum recommended dosing frequency is once per day.
Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg.
Sildenafil tablets may be taken with or without food.
Sildenafil tablets were shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated
[see Contraindications (
4.1), Drug Interactions (
7.1), and Clinical Pharmacology (
12.2)].
When Sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg
[see Warnings and Precautions (
5.5), Drug Interactions (
7.2), and Clinical Pharmacology (
12.2)].
Ritonavir
The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold
[see Warnings and Precautions (
5.6), Drug Interactions (
7.4), and Clinical Pharmacology (
12.3)].
CYP3A4 Inhibitors
Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold
.
Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of sildenafil tablets in these patients resulted in higher plasma levels of sildenafil
[see Use in Specific Populations (
8.5,
8.6,
8.7) and Clinical Pharmacology (
12.3)].
How to take Sildenafil — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Nitrates
Physicians should discuss with patients the contraindication of sildenafil tablets with regular and/or intermittent use of nitric oxide donors, such as organic nitrates or organic nitrites in any form
.
Guanylate Cyclase (GC) Stimulators
Physicians should discuss with patients the contraindication of sildenafil tablets with use of guanylate cyclase stimulators such as riociguat
.
Concomitant Use with Drugs Which Lower Blood Pressure
Physicians should advise patients of the potential for sildenafil tablets to augment the blood pressure lowering effect of alpha-blockers and anti-hypertensive medications. Concomitant administration of sildenafil tablets and an alpha-blocker may lead to symptomatic hypotension in some patients. Therefore, when sildenafil tablets are co-administered with alpha-blockers, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at the lowest dose
. …
Warnings & precautions
Do not take this medicine if: Consistent with its known effects on the nitric oxide/cGMP pathway
, sildenafil tablets were shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated.
After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point
[see Dosage and Administration (
2.3), Drug Interactions (
7.1), and Clinical Pharmacology (
12.2)].
Sildenafil tablets are contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil tablets and REVATIO, or any component of the tablet. Hypersensitivity reactions have been reported, including rash and urticaria
.
Do not use sildenafil tablets in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including sildenafil tablets, may potentiate the hypotensive effects of GC stimulators.
There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including sildenafil tablets, should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment. …
Sildenafil side effects
The following are discussed in more detail in other sections of the labeling:
• Cardiovascular
• Prolonged Erection and Priapism
• Effects on the Eye
• Hearing Loss
• Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives
• Adverse Reactions with the Concomitant Use of Ritonavir
• Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies
• Effects on Bleeding
• Counseling Patients About Sexually Transmitted Diseases
The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Sildenafil tablets was administered to over 3,700 patients (aged 19 to 87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year.
In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for sildenafil tablets (2.5%) was not significantly different from placebo (2.3%).
In fixed-dose studies, the incidence of some adverse reactions increased with dose. …
Drug interactions
Administration of sildenafil tablets with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil tablets were shown to potentiate the hypotensive effects of nitrates
[see Dosage and Administration (
2.3), Contraindications (
4.1), Clinical Pharmacology (
12.2)].
Use caution when co-administering alpha-blockers with sildenafil tablets because of potential additive blood pressure-lowering effects. When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at the lowest dose
[see Dosage and Administration (
2.3), Warnings and Precautions (
5.5), Clinical Pharmacology (
12.2)].
When sildenafil tablets 100 mg was co-administered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic
.
Co-administration of ritonavir, a strong CYP3A4 inhibitor, greatly increased the systemic exposure of sildenafil (11-fold increase in AUC). …
About this medicine
Sildenafil tablets, USP an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1
H-pyrazolo[4,3-
d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula:
Sildenafil citrate is a white or almost white, slightly hygroscopic crystalline powder with a slightly soluble in water and methanol, practically insoluble in hexane and a molecular weight of 666.7.
Sildenafil tablets USP is formulated as blue, film-coated rounded-diamond-shaped tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration. In addition to the active ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, lactose, triacetin, and FD & C Blue #2 aluminum lake. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5fa4920c-ec29-b879-e063-6294a90adcad. Read the full official label on DailyMed.